Announced details
Treatment of advanced solid tumors, including endometrial cancer
The combination therapy enhanced antitumor effects compared with either monotherapy. Tumor regression was observed in the HEC251 and HEC50B models. The treatment was not accompanied by severe body weight loss (more than 20% body weight loss).
PRISM BioLab and Eisai jointly created E7386. Eisai is conducting clinical trials of E7386 and presenting the research at the AACR Annual Meeting.
Headquartered in Bunkyo-ku, Tokyo, Eisai Co.,Ltd. is a pharmaceutical company that developed lenvatinib and is conducting clinical trials of E7386. Other company information: Not disclosed.
NCT04008797 (clinical trial identifier)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Abstract from the American Association for Cancer Research (AACR) Annual Meeting (AACR Annual Meeting 2026)
| Item | Details |
|---|---|
| Names of Products / Services Covered | E7386, LENVIMA® (lenvatinib) |
| Counterparty | Eisai Co.,Ltd. |
| Counterparty overview | Headquartered in Bunkyo-ku, Tokyo, Eisai Co.,Ltd. is a pharmaceutical company that developed lenvatinib and is conducting clinical trials of E7386. Other company information: Not disclosed. |
| Relationship with the Company | PRISM BioLab and Eisai jointly created E7386. Eisai is conducting clinical trials of E7386 and presenting the research at the AACR Annual Meeting. |
| Launch date | From 17 April 2026 to 22 April 2026 (research presentation scheduled at the AACR Annual Meeting) |
| Applicable area | Treatment of advanced solid tumors, including endometrial cancer |
| Registration number and expiry date | NCT04008797 (clinical trial identifier) |
| Quantitative Effects | The combination therapy enhanced antitumor effects compared with either monotherapy. Tumor regression was observed in the HEC251 and HEC50B models. The treatment was not accompanied by severe body weight loss (more than 20% body weight loss). |
| Source | Abstract from the American Association for Cancer Research (AACR) Annual Meeting (AACR Annual Meeting 2026) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In multiple endometrial cancer xenograft models, the combination of E7386 and lenvatinib showed stronger antitumor effects than either monotherapy, and tumor regression was observed in the HEC251 and HEC50B models.